Bruker Corporation
BRKR
주식 순위
#2309
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
주가
$56.53
시가총액
$8.61B
변동 (1일)
2.09%
변동 (1년)
48.33%
국가
US
거래 Bruker Corporation (BRKR)
카테고리
Healthcare
Bruker Corporation (BRKR)의 매출
Jun 2026 기준 매출 TTM: $3.50B
Bruker Corporation의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $3.50B입니다. 2024년에 회사는 $3.37B의 수익을 올렸으며 이는 2023년의 $2.96B 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Bruker Corporation의 수익 기록 (2000 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $3.50B | 1.84% |
| 2025 | $3.44B | 2.08% |
| 2024 | $3.37B | 13.56% |
| 2023 | $2.96B | 17.14% |
| 2022 | $2.53B | 4.67% |
| 2021 | $2.42B | 21.66% |
| 2020 | $1.99B | -4.11% |
| 2019 | $2.07B | 9.34% |
| 2018 | $1.90B | 7.34% |
| 2017 | $1.77B | 9.59% |
| 2016 | $1.61B | -0.77% |
| 2015 | $1.62B | -10.23% |
| 2014 | $1.81B | -1.66% |
| 2013 | $1.84B | 2.68% |
| 2012 | $1.79B | 8.46% |
| 2011 | $1.65B | 26.58% |
| 2010 | $1.30B | 17.08% |
| 2009 | $1.11B | 0.67% |
| 2008 | $1.11B | 102.18% |
| 2007 | $547.58M | 25.64% |
| 2006 | $435.83M | 46.46% |
| 2005 | $297.57M | 4.62% |
| 2004 | $284.42M | 9.11% |
| 2003 | $260.68M | 124.01% |
| 2002 | $116.37M | 25.54% |
| 2001 | $92.69M | 21.00% |
| 2000 | $76.60M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $46.59B | 1,231.15% |
US
|
|
| $35.48B | 913.94% |
IE
|
|
| $25.84B | 638.28% |
US
|
|
| $21.00B | 499.95% |
US
|
|
| - | - |
DE
|
